Cover Image
市場調查報告書

全球充血性心臟衰竭治療藥市場

Global Congestive Heart Failure Drugs Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 323553
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
Back to Top
全球充血性心臟衰竭治療藥市場 Global Congestive Heart Failure Drugs Market 2015-2019
出版日期: 2015年01月28日 內容資訊: 英文 120 Pages
簡介

充血性心臟衰竭的治療,使用血管收縮素轉化酵素抑制劑(ACE抑制劑)/血管收縮素II受體拮抗劑(ARB拮抗劑)、β腎上腺素受體阻斷劑、利尿劑及強心藥等。全球充血性心臟衰竭治療藥市場,從2014年到2019年之間,預計以9.47%的年複合成長率擴大

本報告提供全球充血性心臟衰竭治療藥的各地區市場規模與今後的預測、市場的發展因素與課題、主要供應商分析等,為您概述為以下內容。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品
    • 產品簡介

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 各治療分類的市場

第8章 後期開發平台階段的分子

第9章 地理區分

  • 南北美洲的充血性心臟衰竭治療藥市場
    • 市場規模與預測
  • 歐洲的充血性心臟衰竭治療藥市場
    • 市場規模與預測
  • 亞洲的充血性心臟衰竭治療藥市場
    • 市場規模與預測
  • 其他地區的充血性心臟衰竭治療藥市場
    • 市場規模與預測

第10章 購買標準

第11章 市場成長因素

第12章 成長因素與其影響

第13章 市場課題

第14章 成長因素與課題的影響

第15章 市場趨勢

第16章 趨勢與其影響

第17章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
  • 其他卓越供應商

第18章 主要供應商分析

  • AstraZeneca plc
  • Bristol-Myers Squibb Co.
  • GlaxoSmithKline
  • Merck & Co. Inc.
  • Mylan
  • Novartis AG
  • Pfizer
  • Sanofi SA
  • Valeant Pharmaceuticals International

第19章 相關報告

目錄
Product Code: IRTNTR5062

About Congestive Heart Failure Drugs

Congestive heart failure is a serious and complex condition in which the heart muscles are either damaged or have to work too hard. Although the heart beats, the damaged heart muscles are too weak to pump sufficient oxygen-rich blood to and from the body. ACE inhibitors/ARB antagonists, beta-adrenergic receptor blocking agents, diuretics, and inotropic drugs are the medications available for the treatment of congestive heart failure.

TechNavio's analysts forecast the Global Congestive Heart Failure Drugs market to grow at a CAGR of 9.47 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Congestive Heart Failure Drugs market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of approved drugs and generics used in the treatment of congestive heart failure that are available in the market. The Global Congestive Heart Failure Drugs market can be divided into four segments: ACE Inhibitors/ARB Antagonists, Beta-adrenergic Receptor Blocking Agents, Diuretics, and Inotropic Drugs/Vasodilators.

TechNavio's report, the Global Congestive Heart Failure Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Congestive Heart Failure Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • AstraZeneca
  • Bristol-Myers Squibb
  • GSK
  • Merck & Co.
  • Mylan
  • Novartis
  • Pfizer
  • Sanofi
  • Valeant Pharmaceuticals

Other Prominent Vendors

  • Bayer
  • Bioheart
  • Boehringer Inhelheim
  • Takeda Pharmaceutical
  • Teva Pharmaceutical Industries

Market Driver

  • Increase in Aging Population
  • For a full, detailed list, view our report

Market Challenge

  • Weak Pipeline
  • For a full, detailed list, view our report

Market Trend

  • Increase in Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • 03.2.1. Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Market Segmentation by Therapeutic Class

08. Late Stage Pipeline Molecules

09. Geographical Segmentation

  • 09.1. Congestive Heart Failure Drugs Market in Americas
    • 09.1.1. Market Size and Forecast
  • 09.2. Congestive Heart Failure Drugs Market in Europe
    • 09.2.1. Market Size and Forecast
  • 09.3. Congestive Heart Failure Drugs Market in Asia
    • 09.3.1. Market Size and Forecast
  • 09.4. Congestive Heart Failure Drugs Market in ROW
    • 09.4.1. Market Size and Forecast

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
    • 17.1.2. Mergers and Acquisitions
  • 17.2. Market Share Analysis 2013
  • 17.3. Other Prominent Vendors

18. Key Vendor Analysis

  • 18.1. AstraZeneca plc
    • 18.1.1. Key Facts
    • 18.1.2. Business Overview
    • 18.1.3. Business Segmentation by Revenue 2013
    • 18.1.4. Business Segmentation by Revenue 2011-2013
    • 18.1.5. Sales by Geography
    • 18.1.6. Business Strategy
    • 18.1.7. Key Developments
    • 18.1.8. SWOT Analysis
  • 18.2. Bristol-Myers Squibb Co.
    • 18.2.1. Key Facts
    • 18.2.2. Business Overview
    • 18.2.3. Key Product Offerings
    • 18.2.4. Revenue by Geography
    • 18.2.5. Business Strategy
    • 18.2.6. Key Information
    • 18.2.7. SWOT Analysis
  • 18.3. GlaxoSmithKline
    • 18.3.1. Key Facts
    • 18.3.2. Business Overview
    • 18.3.3. Business Segmentation
    • 18.3.4. Business Segmentation by Revenue 2012 and 2013
    • 18.3.5. Sales by Geography
    • 18.3.6. Pipeline Products
    • 18.3.7. Business Strategy
    • 18.3.8. Key Information
    • 18.3.9. SWOT Analysis
  • 18.4. Merck & Co. Inc.
    • 18.4.1. Key Facts
    • 18.4.2. Business Overview
    • 18.4.3. Business Segmentation by Revenue 2013
    • 18.4.4. Business Segmentation by Revenue 2012 and 2013
    • 18.4.5. Sales by Geography
    • 18.4.6. Business Strategy
    • 18.4.7. Key Developments
    • 18.4.8. SWOT Analysis
  • 18.5. Mylan
    • 18.5.1. Key Facts
    • 18.5.2. Business Overview
    • 18.5.3. Business Segmentation by Revenue 2013
    • 18.5.4. Business Segmentation by Revenue 2011-2013
    • 18.5.5. Geographical Segmentation by Revenue 2013
    • 18.5.6. Business Strategy
    • 18.5.7. Recent Developments
    • 18.5.8. SWOT Analysis
  • 18.6. Novartis AG
    • 18.6.1. Key Facts
    • 18.6.2. Business Description
    • 18.6.3. Business Segmentation
    • 18.6.4. Revenue by Business Segmentation
    • 18.6.5. Revenue Comparison 2012 and 2013
    • 18.6.6. Sales by Geography
    • 18.6.7. Business Strategy
    • 18.6.8. Key Developments
    • 18.6.9. SWOT Analysis
  • 18.7. Pfizer
    • 18.7.1. Key Facts
    • 18.7.2. Business Overview
    • 18.7.3. Business Segmentation by Revenue 2013
    • 18.7.4. Business Segmentation by Revenue 2012 and 2013
    • 18.7.5. Geographical Segmentation by Revenue
    • 18.7.6. Business Strategy
    • 18.7.7. Key Developments
    • 18.7.8. SWOT Analysis
  • 18.8. Sanofi SA
    • 18.8.1. Key Facts
    • 18.8.2. Business Description
    • 18.8.3. Business Segmentation
    • 18.8.4. Revenue by Business Segmentation
    • 18.8.5. Revenue Comparison 2012 and 2013
    • 18.8.6. Sales by Geography
    • 18.8.7. Business Strategy
    • 18.8.8. Key Developments
    • 18.8.9. SWOT Analysis
  • 18.9. Valeant Pharmaceuticals International
    • 18.9.1. Key Facts
    • 18.9.2. Business Overview
    • 18.9.3. Business Segmentation by Revenue 2013
    • 18.9.4. Business Segmentation by Revenue 2012 and 2013
    • 18.9.5. Sales by Geography
    • 18.9.6. Business Strategy
    • 18.9.7. Key Developments
    • 18.9.8. SWOT Analysis

19. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Congestive Heart Failure Drugs Market 2014-2019 (US$ billion)
  • Exhibit 3: Global Congestive Heart Failure Drugs Market Segmentation by Therapeutic Class
  • Exhibit 4: Congestive Heart Failure: Clinical Developmental Pipeline
  • Exhibit 5: Global Congestive Heart Failure Drugs Market by Geographical Segmentation 2014
  • Exhibit 6: Congestive Heart Failure Drugs market in Americas 2014-2019 (US$ billion)
  • Exhibit 7: Congestive Heart Failure Drugs market in Europe 2014-2019 (US$ billion)
  • Exhibit 8: Congestive Heart Failure Drugs market in Asia 2014-2019 (US$ billion)
  • Exhibit 9: Congestive Heart Failure Drugs Market in ROW 2014-2019 (US$ billion)
  • Exhibit 10: Global Congestive Heart Failure Drugs Market by Geographical Segmentation 2014-2019 (in Percent)
  • Exhibit 11: Global Congestive Heart Failure Drugs Market by Geographical Segmentation 2014-2019 (in Revenue)
  • Exhibit 12: Estimated Prevalence of Congestive Heart Failure in Different Age-group (years) in the US
  • Exhibit 13: Age-specific Male Incidence Rates (per 1000 man years) in Congestive Heart Failure
  • Exhibit 14: Age-specific Female Incidence Rates (per 1000 woman-years) in Congestive Heart Failure
  • Exhibit 15: AstraZeneca Year on Year Sales Comparison 2010-2013 (US$ billion)
  • Exhibit 16: GSK Year on Year Sales Comparison 2010-2013 (US$ billion)
  • Exhibit 17: GSK's Total Global Sales of Medicines by Therapeutic Classes 2013 (percentage)
  • Exhibit 18: GSK Coreg Year on Year Sales Comparison 2010-2013 (US$ billion)
  • Exhibit 19: Merck & Co. Year on Year Sales Comparison 2010-2013 (US$ billion)
  • Exhibit 20: Mylan Year on Year Sales Comparison 2010-2013 (US$ billion)
  • Exhibit 21: Novartis Diovan Year on Year Sales Comparison 2010-2013 (US$ billion)
  • Exhibit 22: Novartis Year on Year Sales Comparison 2010-2013 (US$ billion)
  • Exhibit 23: Pfizer Year on Year Sales Comparison 2010-2013 (US$ billion)
  • Exhibit 24: Sanofi Year on Year Sales Comparison 2010-2013 (US$ billion)
  • Exhibit 25: Valeant Pharmaceuticals Year on Year Sales Comparison 2010-2013 (US$ billion)
  • Exhibit 26: Valeant Pharmaceuticals Revenue Breakdown by Product Segments
  • Exhibit 27: AstraZeneca plc: Business Segmentation by Revenue 2013
  • Exhibit 28: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 (US$ million)
  • Exhibit 29: AstraZeneca plc: Sales by Geography 2013
  • Exhibit 30: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
  • Exhibit 31: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
  • Exhibit 32: GlaxoSmithKline: Business Segmentation 2013
  • Exhibit 33: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 34: GlaxoSmithKline: Sales by Geography 2013
  • Exhibit 35: GlaxoSmithKline: Pipeline Products 2013
  • Exhibit 36: Merck & Co. Inc.: Business Segmentation by Revenue 2013
  • Exhibit 37: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 38: Merck & Co. Inc.: Sales by Geography 2013
  • Exhibit 39: Global Congestive Heart Failure Drugs Market: Business Segmentation by Revenue 2013
  • Exhibit 40: Global Congestive Heart Failure Drugs Market: Business Segmentation by Revenue 2011-2013 (US$ billion)
  • Exhibit 41: Global Congestive Heart Failure Drugs Market: Geographical Segmentation by Revenue 2013
  • Exhibit 42: Novartis AG: Business Segmentation
  • Exhibit 43: Novartis AG: Revenue by Business Segmentation 2013
  • Exhibit 44: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 45: Novartis AG: Revenue by Geographical Segmentation 2013
  • Exhibit 46: Pfizer: Business Segmentation by Revenue 2013
  • Exhibit 47: Pfizer: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 48: Pfizer: Geographical Segmentation by Revenue 2013
  • Exhibit 49: Sanofi SA: Business Segmentation
  • Exhibit 50: Sanofi SA: Revenue by Business Segmentation 2013
  • Exhibit 51: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 52: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
  • Exhibit 53: Valeant Pharmaceuticals International: Business Segmentation by Revenue 2013
  • Exhibit 54: Valeant Pharmaceuticals International: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 55: Valeant Pharmaceuticals International: Sales by Geography 2013
Back to Top